Clinical trials: Venous Thromboembolic Event
Circulatory Disease
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total…
- Trial name
- NCT06963320
- Testing
- H001 Capsule 200mg-qd, Enoxaparin Sodium Injection, H001 Capsule 300mg-qd
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Venous Thromboembolism
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm…
- Trial name
- NCT02223260
- Testing
- dabigatran
- Where
- 4 sites in Canada, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Deep Venous Thrombosis
The China Pulmonary Thromboembolism Registry Study
Epidemiological data on pulmonary embolism (PE) in China needs to be updated and reported. The China Pulmonary Thromboembolism Registry Study (CURES) is designed to provide the cross-sectional spectrum and chronological trends of…
- Conditions
- Pulmonary Embolism, Deep Venous Thrombosis, Venous Thromboembolism
- Trial name
- CURES (NCT02943343)
- Testing
- No intervention
- Where
- China
- Volunteers
- 15,000 people
- Sponsor
- China-Japan Friendship Hospital
Thrombosis
Pediatric Catheter-related Thrombosis Imaging Study
This protocol will serve as a pilot study to determine the validity and feasibility of contrast enhanced magnetic resonance imaging (MRI) without and with contrast and/or ultrasound (US) for detection of catheter related deep…
- Trial name
- AESOP (NCT01137578)
- Testing
- Ultrasound, Magnetic Resonance Imaging with Contrast, Magnetic Resonance Imaging without Contrast
- Where
- 26 sites in United States, Argentina and 7 more
- Volunteers
- 151 people
- Sponsor
- Bristol-Myers Squibb
Factor V Leiden, Prothrombin G20210A
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism
This is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending and multiple dose study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of…
- Conditions
- Factor V Leiden, Prothrombin G20210A, Venous Thromboembolism (VTE)
- Trial name
- NCT07430397
- Testing
- CITY-FXI
- Where
- United Kingdom
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- City Therapeutics
Venous Thromboembolism
Venous Thromboembolism Prophylaxis in a Tertiary UAE Hospital: Comparison of Clinical Practice Guidelines.
Study Title:Assessment of Adherence to Guidelines for Thromboprophylaxis in a Tertiary United Arab Emirates (UAE) hospital Study Site: Al Qassimi Hospital, United Arab Emirates Study Objectives: The primary objective of this…
- Trial name
- VTE (NCT01958203)
- Volunteers
- 386 people
- Sponsor
- Ministry of Health, United Arab Emirates
Venous Thromboembolism, Atrial Fibrillation
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
The arrival on the market of direct oral factor Xa and factor IIa inhibitors (dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) and others soon to come) raises novel questions among clinicians confronted with the…
- Trial name
- GIHP-NACO (NCT02185027)
- Testing
- complications and compliance with GIHP recommendations
- Where
- 41 sites in Belgium, France
- Volunteers
- 1,166 people
- Sponsor
- University Hospital, Grenoble
COVID-19, Critical Illness
Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19
Severe COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain.
- Conditions
- COVID-19, Critical Illness, Venous Thromboembolism, Venous Thromboses
- Trial name
- NCT04374617
- Testing
- Duplex ultrasound and Computed Tomography Angiography
- Where
- 3 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Deep Venous Thrombosis, Pulmonary Embolism
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE).
- Trial name
- Highlow (NCT01828697)
- Testing
- Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 1,110 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Venous Thromboembolism
Construction and External Validation of a Predictive Clinico-biological Score of the Risk of Venous Thrombosis in Women Under Combined Oral Contraceptives
the investigators hypothesize that some of these polymorphisms contribute to VTE risk in women using COC, and that their screening could to help assess individual risk of VTE before COC prescription.
- Trial name
- PILGRIM (NCT03309293)
- Testing
- blood samples
- Where
- France
- Volunteers
- 1,454 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Venous Thromboembolism
Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
In individuals with obesity, the optimal dosing and duration of venous thromboembolism (VTE) prophylaxis in settings representing acute medical illness or surgery is limited due to lack of randomized controlled trials (RCTs)…
- Trial name
- NCT05819125
- Where
- United States
- Volunteers
- 21,000 people
- Sponsor
- Sanofi
Venous Thromboembolism
Once Weekly Subcutaneous Ports for the Administration of Anticoagulants
The purpose of this study is to ascertain whether subcutaneous ports are an effective and reliable way to administer the low molecular weight heparin (LMWH) enoxaparin to patients for the prevention or treatment of venous…
- Trial name
- NCT00774748
- Testing
- Insuflon
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of North Carolina, Chapel Hill
Gonarthrosis
Role of Femoral Nerve Block on Prevention of Postoperative Deep Venous Thromboembolism
To investigate whether preemptive analgesic of femoral nerve block could prevent deep venous thromboembolism due to inhibiting the excessive release of neutrophil elastase and inflammatory cytokines.
- Trial name
- NCT02411097
- Testing
- femoral nerve block
- Where
- China
- Volunteers
- 120 people
- Sponsor
- General Hospital of Ningxia Medical University
Venous Thromboembolism
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
- Trial name
- NCT00657150
- Testing
- Enoxaparin, Dabigatran etexilate
- Where
- 108 sites in United States, Australia and 17 more
- Volunteers
- 2,055 people
- Sponsor
- Boehringer Ingelheim
Venous Thrombosis
Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.
The aim of this study is to estimate the incidence of spontaneous and provoked recurrent VTE and the bleeding events during a 10-year follow-up in subjects experiencing a first VTE stratified according to % AT levels and to…
- Trial name
- NCT01382550
- Testing
- long-lasting OAT or 12-month OAT
- Where
- Italy
- Volunteers
- 900 people
- Sponsor
- Federico II University
Venous Thromboembolism
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
- Trial name
- VTE (NCT04041843)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Critical Illness, Sepsis
Neuromuscular Stimulation Versus Intermittent Compression for Venous Thromboembolism Prophylaxis in Critical Care
In this prospective, randomised, open-label, parallel group, feasibility trial; the investigators will objectively assess whether it is feasible to apply the Geko device to critically ill adults for the prevention of venous…
- Conditions
- Critical Illness, Sepsis, Acute Illness, Venous Thromboembolism
- Trial name
- ENSARIA (NCT05208216)
- Testing
- Geko device, Flowtron DVT
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Manchester University NHS Foundation Trust
Pancreatic Cancer, Venous Thromboembolism
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy.
- Trial name
- NCT00966277
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- M.D. Anderson Cancer Center
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals